摘要
目的:探索检测血清胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、胃泌素-17(G-17)在萎缩性胃炎及胃癌中的诊断价值。方法:收集医院2015年2月至12月门诊及住院的慢性非萎缩性胃炎44例(非萎缩性胃炎组),慢性萎缩性胃炎47例(萎缩性胃炎组),早期胃癌42例(胃癌组)。采用酶联免疫吸附试验(ELISA)测定各组血清PGⅠ、PGⅡ、G-17的水平,同时计算PGⅠ/PGⅡ的比值(PGR),比较各组指标间的差异,同时绘制各指标筛查萎缩性胃炎及胃癌的受试者工作曲线(ROC)曲线,分别评价其诊断价值。结果:胃癌组及萎缩性胃炎组的血清PGⅠ、PGR水平较非萎缩性胃炎组明显下降,且胃癌组下降更明显,差异均具有统计学意义(P<0.05),萎缩性胃炎组血清PGⅡ显著低于非萎缩性胃炎组,差异均具有统计学意义(P<0.05);胃癌组的血清G-17水平较非萎缩性胃炎组及萎缩性胃炎组均升高,差异有统计学意义(P<0.05)。血清PGⅠ筛查萎缩性胃炎的最佳界值为PGⅠ<90 ng/m L,其灵敏度和特异度分别为71.5%和51.0%,血清PGR筛查萎缩性胃炎的最佳界值为PGR<8,其灵敏度和特异度分别为71.9%和54.0%,血清G-17筛查萎缩性胃炎的最佳界值为G-17<5 pmol/L,其灵敏度和特异度分别为66.1%和64.0%。血清PGⅠ筛查胃癌的最佳界值为PGⅠ<73 ng/m L,其灵敏度和特异度分别为86.0%和74.9%;血清PGR筛查胃癌的最佳界值为PGR<3,其灵敏度和特异度分别为90.2%和62.5%;血清G-17筛查胃癌的最佳界值为G-17<4 pmol/L,其灵敏度和特异度分别为62.5%和61.3%。结论:胃癌及萎缩性胃炎患者血清PGⅠ、PGR水平下降明显,且胃癌患者的血清G-17异常升高,血清PG联合GS-17测定可用于萎缩性胃炎及胃癌的早期筛查。
Objective： To research the diagnostic value of measuring serum pepsinogen I（PGI）,pepsinogen II（PGII） and gastrin-17 （G-17） for atrophic gastritis and gastric cancer. Methods： A total of 44 patients were diagnosed with non-atrophic gastritis（non-atrophic gastritis group）, 47 patients were chronic atrophic gastritis（atrophic gastritis group）,42 were gastric cancer（gastric cancer group）were en- rolled in the hospital February 2015 to December 2015.The serum PGI, PGII and G-17 levels were detected by enzyme-linked im- munosorbent assay （ELISA）, and PGUII ratio （PGR） was calculated, compared above indexes in different groups, and drew the receiver operating curve （ROC） of above indexes, and analyzed their diagnostic value. Results： The levels of serum PGI and PGR in gastric cancer group and chronic atrophic gastritis group were significantly decreased than that of non-atrophic gastritis group, and gastric cancer group decreased more, the differences were statistically significant （P〈0.05）, the level of PGII in atrophic gastritis group was lower than non-at- rophic gastritis group, the difference was statistically significant （P〈0.05）, the level of serum G-17 in gastric cancer were significantly in- creased than chronic atrophic gastritis and non-atrophic gastritis group, the differences were statistically significant （P〈0.05）. The opti- mal value of PGI screening for atrophic gastritis was PGI〈90 ng/mL, its sensitivity and specificity were 71.5% and 51.0%, respectively. The optimal value of PGR screening for atrophic gastritis was PGR〈8, its sensitivity and specificity were 71.9% and 54.0%, respectively. The optimal value of G-17 screening for atrophic gastritis was G-17〈5 pmol/L, its sensitivity and specificity were 66.1% and 64.0%, re- spectively. The optimal value of PGI screening for gastric cancer was PGI〈73 ng/mL, its sensitivity and specificity were 86.0% and 74.9%, respectively. The optimal value of PGR screening for gastric cancer was PGR〈3
作者
薛辉
辛凤池
穆素恩
杨俭
赵树巧
XUE Hui XIN Feng-chi MU Su-en YANG Jian ZHA O Shu-qiao(Third Department of Gastroenterology, The First Hospital of Shijiazhuang, Shijiazhuang, Hebei, 050011, China)
出处
《现代生物医学进展》
CAS
2017年第11期2119-2122,共4页
Progress in Modern Biomedicine
基金
2014年度石家庄市科学技术研究与发展指导计划项目(141462833)
关键词
胃蛋白酶原
胃泌素
萎缩性胃炎
胃癌
早期诊断
Pepsinogens
Gastrins
Atrophic gastritis
Gastric cancer
Early diagnosis
